comparemela.com

Jeff Mazzeo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

William Benzing | Obituary | Commercial News

Waters Peptide Multi-Attribute Method for BioAccord System Boosts Innovator

May 11 2021 Waters Corporation (NYSE:WAT) has introduced a new peptide multi-attribute method (MAM) workflow for the Waters™ BioAccord™ LC-MS System, enabling drug development, manufacturing, and QC scientists to monitor efficacy and safety through the analysis of critical quality attributes (CQAs) of monoclonal antibodies (mAbs) and other protein-based drugs. “The BioAccord System moves attribute-based monitoring out of centralised MS labs and into the hands of more scientists in regulated and quality control laboratories who may not have extensive experience operating mass spectrometers,” said Jeff Mazzeo, Ph.D., Vice President – Global Marketing and Scientific Operations, Waters Corporation. “With this new method for the BioAccord System on the waters connect platform, scientists have a single, sensitive multiplexed method to accurately assess the most important attributes of protein-based drugs that enable rapid decision-making for product

Waters Corporation: Waters and Genovis Collaborate to Develop Efficient Workflows for Biopharmaceutical Characterization

Waters Corporation: Waters and Genovis Collaborate to Develop Efficient Workflows for Biopharmaceutical Characterization NEWS SUMMARY: Collaboration intended to bring speed and simplicity to bio-characterization workflows Automated workflows to cut the time and effort required to monitor critical quality attributes of biotherapeutics in regulated laboratories Waters and Genovis share goal of advancing the science behind the analysis of glycoproteins and protein therapeutics Waters Corporation (NYSE:WAT) and Genovis AB (Nasdaq First North Growth Market) are formally collaborating to develop and market complete routine biopharmaceutical characterization workflows based on the Waters BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. The goal of the collaboration is to develop automated workflows for the rapid and consistent characterization of critical quality attributes (CQAs) of monoclonal antibodies (mAbs) and other protein-based drugs in bioprocess de

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.